Research programme: stromal vascular fraction cell therapies - IntelliCell BioSciences

Drug Profile

Research programme: stromal vascular fraction cell therapies - IntelliCell BioSciences

Alternative Names: Adult autologous vascular fraction cells - Intellicell Biosciences; SVFC - Intellicell Biosciences

Latest Information Update: 06 Aug 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator IntelliCell BioSciences
  • Developer IntelliCell BioSciences; University of Arizona
  • Class Cell therapies; Stem cell therapies
  • Mechanism of Action Cell replacements; Stem cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Heart failure; Osteoarthritis

Most Recent Events

  • 01 Aug 2014 IntelliCell Biosciences files a pre-IND with the US FDA for Osteoarthritis (knee)
  • 29 Apr 2014 Preclinical trials in Heart failure in USA (IV)
  • 29 Apr 2014 Preclinical trial for Heart failure in USA (Intramyocardial)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top